Peter the Bridge, Saint Petersburg, Russia

NEOMED Announces Appointment of Dr. Laurence Rulleau and Mr. Paul Buron to Its Board of Directors

April 9th, 2015 |Announcement| No Comments

NEOMED announced today the appointment of two new members to its Board of Directors. Joining the Board are Dr. Laurence Rulleau, Principal at CTI Life Sciences, and Mr. Paul Buron, Executive Vice President and Chief Financial Officer of the Business Development Bank of Canada (BDC).

Dr. Laurence Rulleau currently serves as Principal at CTI Life Sciences, a Montreal-based life sciences venture capital firm. Prior to joining CTI, she served as a life sciences analyst covering the Canadian sector for more than 10 years. She worked at different firms including Desjardins Securities, Yorkton Securities, and Blackmont Securities. She was involved in numerous mergers and acquisitions as well as IPOs. More recently she served as Vice-President Business Development of Univalor, the technology transfer office of Montreal’s university and affiliated schools. Under her responsibility at Univalor in the last three years, more than 40 licences with the industry were signed and eight companies started. Dr. Rulleau has a Masters in Biology from Université du Quebec à Montreal (UQAM) and a PhD from Université de Montréal executed at the Montreal Clinical Research Institute

Mr. Paul Buron has been the Executive Vice-President and Chief Financial Officer of the BDC since 2006 and assumed the additional title of Chief Risk Officer in 2015. Mr. Buron has over 30 years of experience in finance. At BDC, he is responsible for finance, risk management, and treasury, as well as corporate strategy and planning. Before joining BDC, he held leadership positions in major corporations, such as Société générale de financement du Québec, Donohue Inc., and the TVA Group Inc., where he assumed responsibility for television operations and regional stations in addition to his role as Senior Vice President and Chief Financial Officer. He holds a Bachelor of Business Administration from HEC Montréal and is a member of the Ordre des comptables agréés du Québec.

“I am extremely pleased to announce the appointment of Laurence and Paul to our Board of Directors. The addition of two such qualified professionals to our ranks will help us as we continue to work to bring innovative approaches to support the growth and success of the Canadian life sciences ecosystem. Both Laurence and Paul bring a long history of personal success, significant business acumen, and professional networks that will bring great value to the continued evolution and strategic direction of NEOMED,” said Donald Olds, Chairman of NEOMED’s Board of Directors. “On behalf of the entire Board and NEOMED’s management, I am very pleased to welcome them as directors and look forward to benefiting from their valuable perspectives,” he added.

NEOMED is governed by an independent Board of Directors, composed of representatives from the biotechnology and pharmaceutical industries, the academic milieu, and government. The Board plays an active role at both corporate and strategic levels, providing guidance and support to NEOMED’s experienced management team. These appointments raise the number of NEOMED Board members to 11.





NEOMED is a not-for-profit organization whose mission is to foster the development of promising therapeutic approaches emerging from academia and biotechnology companies. Created in 2012, NEOMED supports the development of projects up to the stage of human proof of concept. NEOMED operates in a virtual mode using the services of the NEOMED Institute. The Institute is an open-access drug discovery hub with two high-tech research and development facilities; one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, NEOMED’s biologics and vaccine division, is located in Laval.

NEOMED is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de l’Innovation et des Exportations du Québec, and the Networks of Centres of Excellence (NCE) of Canada. For more information, please visit our website:


For more information, please contact:

Mounia Azzi, Ph.D.
Director, Scientific Affairs

7171 Frederick-Banting
Montréal (Québec) H4S 1Z9


Share this

Similar News

image articles
5 June 2018

Pfizer Canada Invests in the NEOMED Institute to Further Support Growth in Quebec’s Life Sciences Sector

Read complete news
image articles
31 May 2018

GSK and NEOMED call for proposals for innovative early stage human therapeutic projects in Quebec

Read complete news
© 2018 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia